Balchem Corporation reported second quarter 2026 financial results for the period ended June 30, 2026. The company achieved record quarterly net sales of $284.0 million, an 11.2% increase year-over-year, alongside GAAP net earnings of $44.6 million and adjusted EBITDA of $77.9 million. Diluted GAAP earnings per share rose to $1.39 from $1.17 in the prior year period. Balchem also amended its senior secured revolving credit facility, increasing borrowing capacity from $550 million to $650 million and extending maturity to July 24, 2031. The company repurchased $28.8 million of common stock during the quarter. Balchem Corporation operates in the specialty chemicals industry, providing ingredients for human nutrition, animal health, and industrial applications.

On July 24, 2026, Balchem Corporation entered into Amendment No. 1 to its Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A. and JPMorgan SE. The amendment increases the aggregate revolving commitment from $550 million to $650 million and extends the maturity date from July 27, 2027, to July 24, 2031. Key terms include enabling the Foreign Borrower to borrow funds, eliminating a 10 basis point SOFR adjustment, and reducing applicable margins for loans at Tier 3 and 4 leverage levels by 12.5 basis points. Balchem also entered into an Omnibus Reaffirmation and Amendment Agreement regarding its existing Security and Pledge Agreement. Balchem Corporation is a specialty chemical company providing ingredients and nutritional solutions.